CYCLOPENTHIAZIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H18ClN3O4S2
Molecular Weight	379.883
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NS(=O)(=O)C1=C(Cl)C=C2NC(CC3CCCC3)NS(=O)(=O)C2=C1

InChI

InChIKey=BKYKPTRYDKTTJY-UHFFFAOYSA-N

InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)

HIDE SMILES / InChI

Description

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Solute carrier family 12 member 3 3	Inhibitor 8,297

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 567	Primary	Approved 8,429	NAVIDREX
Edema 22	Primary	Approved 8,429	NAVIDREX
Heart failure 103	Primary	Approved 8,429	NAVIDREX

PubMed

PubMed

Show entries

Title	Date	PubMed
		4235748
Effect of long-term diuretic treatment on body-potassium in heart-disease.	1976 Nov 13	62899
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease.	1985 Sep	4041299
Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.	1987 Apr	3297616
Is nifedipine a suitable first-line treatment for essential hypertension in general practice?	1987 Nov	3330028